Constellation Brands, Inc. (STZ) Stock Analysis

38.0/100
Sell Not Halal Consumer Defensive
Price $145.61
Market Cap $24.64B
52-Week Change +12.28%

Is STZ a good investment?

Constellation Brands, Inc. (STZ) has a Plutrex AI rating of 38.0/100 as of November 12, 2026, indicating a Sell consensus. The stock is not classified as halal-compliant. Key strength: Elite profitability moat with operating margin 32.79% (+26% vs industry), net margin 20.90% (+53% vs industry), and ROE 23.92% (+93% vs industry) — these margins reflect genuine durable competitive advantages from Modelo and Corona premium positioning. Main concern: Structural growth collapse deepening: 5-year forward EPS CAGR 2.79% is now 70% below industry average 9.22% (prior gap was 76% vs a different peer set); PEG has WORSENED from 4.26x to 4.63x (+8.7%) while stock price rose 11%; STZ is now 29% above my fair entry zone of $108-$115 with ZERO improvement in the thesis that warranted that lower entry.

Investment Summary

STZ is a high-quality franchise in structural growth deceleration, now trading at $144.12 — a full 11% above my prior entry zone midpoint of $111.50 established 14 days ago. The investment thesis is fundamentally unchanged and has actually deteriorated on valuation: PEG has risen from 4.26x to 4.63x (+8.7%), P/E has expanded from 11.64x to 12.93x (+11.1%), while the analyst consensus target barely moved ($147.92 to $147.46, -0.3%), implying only 2.3% upside. The stock has rallied INTO deteriorating fundamentals. Core metrics: Operating margin 32.79% (best-in-class, +26% vs industry 25.99%), net margin 20.90% (+53% vs industry 13.66%), ROE 23.92% (+93% vs industry 12.41%), FCF $1.839B — these are genuinely elite. But 5-year forward EPS CAGR of 2.79% is 70% below the industry average of 9.22%, YoY EPS growth is -4.7%, D/E is 1.06x (45% above industry 0.733x), and cash is a dangerously thin $98.5M. The Q2 beat (comparable EPS $3.74, +3% YoY vs estimates) is acknowledged but the structural growth deficit remains catastrophic. At $144, the stock is now 29% above where I would want to own it. Avoid new positions here.

Key Strengths

Key Concerns

Plutrex 10-Factor AI Breakdown

Financial Health
38/100
Growth Potential
18/100
Valuation
25/100
Profitability
88/100
Debt Management
28/100
Analyst Sentiment
48/100
Technical Momentum
30/100
Insider Confidence
40/100
News Sentiment
62/100

Fundamental Analysis

STZ's fundamental profile is a tale of two cities. PROFITABILITY (elite): Gross margin 50.78%, operating margin 32.79% (industry avg 25.99%), net margin 20.90% (industry avg 13.66%), ROE 23.92% (industry avg 12.41%) — all best-in-class. FCF of $1.839B is the valuation floor anchor. GROWTH (catastrophic): 5-year forward EPS CAGR 2.79% vs industry 9.22% (-69.7%), YoY EPS growth -4.7%, next-year EPS estimate N/A (itself a warning flag vs industry avg +7.28% next year). Revenue growth of 6.1% is marginally above industry 5.74% but insufficient given the EPS drag. VALUATION (expensive on growth-adjusted basis): P/E 12.93x appears modest vs industry 17.82x, but PEG 4.63x is 62% above industry 2.86x — meaning investors pay MORE per unit of growth than peers despite a seemingly cheaper absolute multiple. This is the mathematical trap: low P/E / near-zero growth = high PEG = expensive. HEALTH: D/E 1.06x (45% above industry 0.733x), cash $98.5M (dangerously thin for the enterprise scale), partially offset by $1.839B FCF. FCF-based fair value: $1.839B / 6.2% cap rate (9% discount - 2.8% growth) = ~$29.7B enterprise value; backing out net debt suggests equity value modestly below current $27-28B market cap. The stock is modestly to moderately overvalued on FCF basis and significantly overvalued on PEG basis.

News Sentiment

Constellation Brands delivered a modest win on Wall Street, but the celebration may be short-lived. The maker of Corona and Modelo beers posted better-than-expected second-quarter results, with comparable earnings per share growing 3% to $3.74 — edging past what analysts had predicted. It sounds like good news, and in isolation, it is. But the headline 'Constellation Brands: Still A Modest Buy, But Not For The Enterprising Individual' captures the market mood perfectly: this is a company that's doing fine, not thriving. The bigger story is that STZ is battling a softening alcohol market. As one headline asked ominously, 'What an Empty Wine Glass Says About the Next Recession' — consumers are drinking less, and premium brands are feeling the squeeze. Meanwhile, the company is 'getting creative to bring back beer drinkers,' as noted in prior coverage — a defensive posture, not an offensive growth strategy. There are genuine bright spots. The completion of the Veracruz plant should ease capacity bottlenecks and improve margins. The headline 'Constellation Brands: Disciplined RTD Expansion Further Future-Proofs The Portfolio' points to smart positioning in ready-to-drink beverages. And even Jim Cramer highlighted STZ among consumer stocks worth watching beyond tech. But for investors eyeing a big return? The math is challenging. With the stock near analysts' target prices and long-term earnings growth projected at a meager 2.8% annually, STZ is better described as a steady ship than a growth rocket.

Risk Assessment

PRIMARY RISK: At $144.12, STZ offers only 2.3% upside to analyst consensus ($147.46) with downside to FCF-floor fair value of $108-$115 (a potential -20% to -25% decline). The risk/reward is deeply unfavorable at current prices. STRUCTURAL RISKS: (1) Growth deceleration is confirmed and worsening — EPS CAGR 2.79% vs industry 9.22%; at this growth rate, any multiple compression (from 12.93x toward a 10x justified by growth) implies $112 price or lower. (2) D/E 1.06x with only $98.5M cash creates vulnerability if alcohol demand softens further or interest rates remain elevated. (3) Softening overall alcohol market demand (noted in news) could pressure already-declining EPS further. MITIGATION: Hold existing positions (don't add); FCF of $1.839B provides strong floor; Veracruz plant completion is a catalyst; Modelo/Corona brand strength is durable. FOR NEW BUYERS: Wait for $108-$115 entry zone. The 11% stock rally since my prior report on NO fundamental improvement represents a deteriorating risk/reward that disciplined investors should not chase.

Related Halal Stocks

Related Stocks

Frequently Asked Questions

Is STZ a halal stock?

No, Constellation Brands, Inc. (STZ) is currently not classified as halal by AAOIFI criteria.

What is Plutrex's AI rating for STZ?

Constellation Brands, Inc. (STZ) has a Plutrex AI rating of 38.0/100 with a Sell consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.

Is STZ a good investment?

According to Plutrex AI, STZ has a Sell rating (38.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.

How can I invest in STZ?

US stocks like STZ can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.

What are the main risks of investing in STZ?

Plutrex AI identifies the main risks for STZ by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.

Chat with ElBarake AI about STZ

Ask anything about this stock and get an instant AI-powered answer — free, no signup required.

Open STZ in ElBarake